Fair Trade & Ethical Sourcing

No specific, quantitative data points for CRNX.US regarding fair trade and ethical sourcing practices were found across the provided articles.

All articles indicated that no relevant data could be extracted or the requested pages were not found.

Kind to Animals

Crinetics Pharmaceuticals exploits animals for product testing, as stated in a company report, and commissioned tests on 80 beagle puppies.

The company stated that the euthanizing of some dogs cannot be avoided due to U.S. Food and Drug Administration (FDA) requirements, indicating that legal mandates override alternatives. Crinetics contracted with Inotiv for studies involving over 6,000 animals, including 250 dogs, 500 primates, 62 minipigs, and over 5,100 mice and rats. There is no evidence of formal collaborations on animal-free research and development, nor is there information on the percentage of the R&D budget invested in animal-free technologies. The company has not taken a public position on animal welfare legislation or engaged in advocacy for higher standards, despite receiving a joint letter from 170 legislators in 32 states calling for the release of dogs from testing.

No War, No Weapons

The provided articles do not contain specific, concrete data points for any of the KPIs related to the 'No War, No Weapons' ethical value. The company's core business is biopharmaceuticals, and there is no evidence of involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, or any peacebuilding initiatives. While the Code of Conduct mentions compliance with U.S. export control laws, this is a policy statement and not a quantifiable outcome or specific action regarding sales to embargoed regimes.

Therefore, no KPIs can be scored based on the provided information.

Respect for Cultures & Communities

The provided articles do not contain specific, quantitative data points relevant to any of the KPIs for "Respect for Cultures & Communities." Information regarding formal partnerships with indigenous or local community groups, revenue reinvested in local community development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms for community concerns, average complaint resolution times, FPIC participation rates, community governance inclusion, cultural preservation investment, local procurement share, indigenous supplier engagement, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion is not present.

The Patient Leadership Council described focuses on patient engagement in drug development, not on broader local or indigenous community engagement or cultural aspects as defined by the value.